1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-ethoxyethanol | 260972-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-ethoxyethanol
• 英文别名: WR308309；2,8-Bis(trifluoromethyl)-α-ethoxymethyl-4-quinolinemethanol；2,8-Bis(trifluoromethyl)-alpha-ethoxymethyl-4-quinolinemethanol；1-[2,8-bis(trifluoromethyl)quinolin-4-yl]-2-ethoxyethanol
• CAS: 260972-62-1
• 化学式: C₁₅H₁₃F₆NO₂
• 分子量: 353.264
• InChiKey: HAGCRJSBUXFFFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-[2,8-二(三氟甲基)-4-喹啉基]环氧乙烷 、 乙醇 在 氰胺 作用下， 反应 2.0h， 以65%的产率得到1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-ethoxyethanol
  参考文献：
  名称：

  甲氟喹和非哌啶类似物对氨基酸外排和红细胞性恶性疟原虫生长的平行抑制：对抗疟药作用机理的暗示。

  摘要：

  尽管甲氧喹（MQ）在某些患者中引起令人不安的精神副作用，但由于其对所有疟原虫的活性，给药方便性以及对儿童和孕妇的相对安全性，已被用于疟疾的预防和治疗。然而，目前尚无关于MQ的抗疟疾作用机制的共识。MQ机制的两个主要假设是抑制血红素结晶和抑制宿主细胞血红蛋白内吞作用。在本报告中，我们显示MQ是一种有效且快速的氨基酸，可从完整的寄生红细胞中排出氨基酸，这是衡量宿主血红蛋白内吞和分解代谢体内速率的一种方法。为了进一步探讨MQ的作用机理，我们比较了MQ和18个非哌啶类似物对氨基酸外排和寄生虫生长的影响。在这些密切相关的化合物中，对于寄生虫生长和亮氨酸外排的50％抑制浓度（IC50）值，观察到了近4个对数单位的极佳相关性。这些数据和其他观察结果与以下假设相吻合：这些化合物的抗疟疾作用源自抑制血红蛋白内吞作用。

  DOI：

  10.1016/j.bmcl.2016.08.005

文献信息

• Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action
  作者：Maryam Ghavami、Christie H. Dapper、Seema Dalal、Kristina Holzschneider、Michael Klemba、Paul R. Carlier

  DOI：10.1016/j.bmcl.2016.08.005

  日期：2016.10

  non-piperidine analogs on amino acid efflux and parasite growth. Among these closely related compounds, an excellent correlation over nearly 4 log units is seen for 50% inhibition concentration (IC50) values for parasite growth and leucine efflux. These data and other observations are consistent with the hypothesis that the antimalarial action of these compounds derives from inhibition of hemoglobin endocytosis

  尽管甲氧喹（MQ）在某些患者中引起令人不安的精神副作用，但由于其对所有疟原虫的活性，给药方便性以及对儿童和孕妇的相对安全性，已被用于疟疾的预防和治疗。然而，目前尚无关于MQ的抗疟疾作用机制的共识。MQ机制的两个主要假设是抑制血红素结晶和抑制宿主细胞血红蛋白内吞作用。在本报告中，我们显示MQ是一种有效且快速的氨基酸，可从完整的寄生红细胞中排出氨基酸，这是衡量宿主血红蛋白内吞和分解代谢体内速率的一种方法。为了进一步探讨MQ的作用机理，我们比较了MQ和18个非哌啶类似物对氨基酸外排和寄生虫生长的影响。在这些密切相关的化合物中，对于寄生虫生长和亮氨酸外排的50％抑制浓度（IC50）值，观察到了近4个对数单位的极佳相关性。这些数据和其他观察结果与以下假设相吻合：这些化合物的抗疟疾作用源自抑制血红蛋白内吞作用。
• 4-Quinolinemethanol derivatives as purine receptor antagonists (1)
  申请人：Vernalis Research Limited

  公开号：US06583156B1

  公开（公告）日：2003-06-24

  Use a compound of formula (I) wherein: R1 is hydrogen or alkyl; R2 and R3 are independently selected from hydrogen, alkyl, aryl and heterocyclyle or together may form a ring or R1 and R2 or R3 together may form an oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1 and R4 to R9 are hydrogen, R2 or R3 is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial. Said disorders are neurodegenerative disorders or movement disorders selected from Parkinson's disease or progressive supernuclear palsy, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.

  使用式(I)的复合物，其中：R1是氢或烷基；R2和R3独立选择自氢、烷基、芳香基和杂环基，或者一起可以形成环，或者R1和R2或R3一起可以形成含氧的、可选融合环的药物可接受的盐或前药；但是，当R1和R4到R9是氢时，R2或R3不是3-甲氧基-4-苄氧基苯基或2-二甲基氨基乙氧甲基。用于制造治疗或预防阻断嘌呤受体，特别是腺苷受体，更特别是A2A受体可能有益的紊乱药物。所述紊乱是神经退行性紊乱或运动紊乱，包括帕金森病或进行性核上性麻痹、亨廷顿病、多系统萎缩、皮质基底节变性、威尔逊病、哈勒罗登-斯帕茨病、进行性苍白球萎缩、多巴响应性肌张力障碍、痉挛、阿尔茨海默病或其他导致运动障碍的基底节疾病。
• Structure–activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum
  作者：Erin Milner、William McCalmont、Jayendra Bhonsle、Diana Caridha、Dustin Carroll、Sean Gardner、Lucia Gerena、Montip Gettayacamin、Charlotte Lanteri、ThuLan Luong、Victor Melendez、Jay Moon、Norma Roncal、Jason Sousa、Anchalee Tungtaeng、Peter Wipf、Geoffrey Dow

  DOI：10.1016/j.bmcl.2010.01.001

  日期：2010.2

  Utilizing mefloquine as a scaffold, a next generation quinoline methanol (NGQM) library was constructed to identify early lead compounds that possess biological properties consistent with the target product pro. le for malaria chemoprophylaxis while reducing permeability across the blood-brain barrier. The library of 200 analogs resulted in compounds that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Herein we report selected chemotypes and the emerging structure activity relationship for this library of quinoline methanols. Published by Elsevier Ltd.
• US6583156B1
  申请人：——

  公开号：US6583156B1

  公开（公告）日：2003-06-24
• [EN] NEXT GENERATION QUINOLOINE METHANOLS<br/>[FR] QUINOLÉINE MÉTHANOLS DE NOUVELLE GÉNÉRATION
  申请人：US OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY ON BEHALF OF U S

  公开号：WO2010144101A1

  公开（公告）日：2010-12-16

  The present invention relates to new quinoline methanol derivatives and therapeutic compostions comprising one or more quinoline methanol derivatives. These compositons are useful in the reduction, treatment, or prevention of malaria, microbial, parasitic, protozoan, bacterial, and fungal diseases and conditions. Advantageously, compositions of the invention are less able to cross the blood-brain barrier than mefloquine and as a result produce fewer adverse side effects to the central nervous system as compared to mefloquine.